Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt Sells 5,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $45.52, for a total value of $227,600.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $590,166.80. This trade represents a 27.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Amy Bachrodt also recently made the following trade(s):

• On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $39.15, for a total transaction of $195,750.00.
• On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total transaction of $405,800.00.
• On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.08, for a total transaction of $200,400.00.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $44.58 on Tuesday. The company has a market capitalization of $2.15 billion and a PE ratio of -2.13. The company has a 50 day moving average price of $40.12 and a 200-day moving average price of $28.36. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $47.36.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock valued at $135,000 after purchasing an additional 977 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after purchasing an additional 1,455 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Maze Therapeutics during the 3rd quarter worth $52,000.

Wall Street Analysts Forecast Growth

MAZE has been the subject of a number of research reports. Guggenheim reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th. HC Wainwright upped their price target on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. increased their price objective on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, September 29th. BTIG Research boosted their price objective on shares of Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Wedbush upped their target price on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.